This page shows what was measured, who it was measured in, and what that does not settle.
What PEMETREXED, (R)- does in the body
Recurrent, metastatic non-squamous NSCLC after prior chemotherapy
From the FDA-approved label: Pemetrexed for injection, is a folate analog metabolic inhibitor that exerts its action by disrupts folate-dependent metabolic processes essential for cell replication. In vitro studies show that pemetrexed inhibits thymidylate synthase (TS), dihydrofolate reductase, and glycinamide ribonucleotide formyltransferase (GARFT), which are folate-dependent enzymes involved in the de novo biosynthesis of thymidine and purine nucleotides. Pemetrexed is taken into cells by membrane carriers such as the reduced folate carrier and membrane folate binding protein transport systems. Once in the cell, pemetrexed is converted to polyglutamate forms by the enzyme folylpolyglutamate synthetase.
What happened in people
RNAWiki has not yet published a reviewed conclusion for this use.
§ A fixed RNAWiki sentence
Where this came from
Wording RNAWiki always uses, not a finding about this substance.
No reviewed claim names a result for any goal on this record.
No source is stored against this line.
The limit that matters most
Not recorded.
Where it acts
Not recorded.
Kind of result
No result is published, so no kind of result applies yet
Supervision
Professional supervision is normally required. A regulator classifies this substance in a way that restricts how it is supplied.
What the registries record it as
Its recorded molecular formula is C20H19N5Na2O6, weighing 516.41.
US prescribing information · 0f006b06-ab85-423d-ba0c-dfc3fc25844e · read 2026-08-30
Where each sentence above came from
No recorded sentence describes the change this makes in a way that stands on its own. The page opens with what it is taken for instead, and the recorded explanation follows below.
Shown as the opening line on this page.
No statement of the main limit is recorded.
The four opening statements run to 114 words.
Words this page uses
Four words worth knowing first
Chosen from what this page shows, with each one explained before the word it depends on.
Formulation
A formulation is the exact made-up form a substance comes in.
A picture of it, and where the picture fails
It is like the difference between a whole bean and instant coffee.
Where that stops being true. Coffee tastes different. A formulation can change how much reaches the blood.
What people get wrong. Two products with the same name are assumed to behave the same. They often do not.
The specific composition and physical form of a product, including salt, excipients and release profile.
What happened in people◇Read from sources, not yet reviewed
What happened in people
Each card is one study: the exact question it asked, who was in it, and whether it showed what it set out to show.
Correlation between Adverse events (AEs) and gene profile
✗ The study did not show it
Who was studied
NCT05055908
How many people
12000
Study design
Phase 3
Compared against
Not recorded for this study
Kind of result
A number that stands in for health
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated
What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.
The limits of this study, and where it came from
Main limit. No limitation is recorded for this study.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route. Intravenous
Interval reported. Not recorded in this summary
Written into the record, not signed off as a reviewed claim.
openFDA Drugs@FDA · a recorded source, not a stored snapshot
openFDA NDC Directory · a recorded source, not a stored snapshot
openFDA SPL label · a recorded source, not a stored snapshot
PubChem PUG-REST · a recorded source, not a stored snapshot
Central and local clinical genotyping to facilitate accrual to the adjuvant Intergroup studies, E4512 and A081105
✗ The study did not show it
Who was studied
NCT02194738
How many people
8300
Study design
Not applicable
Compared against
Not recorded for this study
Kind of result
A number that stands in for health
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated
What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.
The limits of this study, and where it came from
Main limit. No limitation is recorded for this study.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route. Intravenous
Interval reported. Not recorded in this summary
Written into the record, not signed off as a reviewed claim.
openFDA Drugs@FDA · a recorded source, not a stored snapshot
openFDA NDC Directory · a recorded source, not a stored snapshot
openFDA SPL label · a recorded source, not a stored snapshot
PubChem PUG-REST · a recorded source, not a stored snapshot
Progression-free survival (PFS)
✗ The study did not show it
Who was studied
NCT04322890
How many people
6000
Study design
Phase 2
Compared against
Not recorded for this study
Kind of result
Living longer, or avoiding a major event
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated
What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.
The limits of this study, and where it came from
Main limit. No limitation is recorded for this study.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route. Intravenous
Interval reported. Not recorded in this summary
Written into the record, not signed off as a reviewed claim.
openFDA Drugs@FDA · a recorded source, not a stored snapshot
openFDA NDC Directory · a recorded source, not a stored snapshot
openFDA SPL label · a recorded source, not a stored snapshot
PubChem PUG-REST · a recorded source, not a stored snapshot
Progression-free survival (PFS)
✗ The study did not show it
Who was studied
NCT06824792
How many people
3000
Study design
Phase 4
Compared against
Not recorded for this study
Kind of result
Living longer, or avoiding a major event
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated
What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.
The limits of this study, and where it came from
Main limit. No limitation is recorded for this study.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route. Intravenous
Interval reported. Not recorded in this summary
Written into the record, not signed off as a reviewed claim.
openFDA Drugs@FDA · a recorded source, not a stored snapshot
openFDA NDC Directory · a recorded source, not a stored snapshot
openFDA SPL label · a recorded source, not a stored snapshot
PubChem PUG-REST · a recorded source, not a stored snapshot
Progression-Free Survival Per BICR
✗ The study did not show it
Who was studied
NCT02477826
How many people
2747
Study design
Phase 3
Compared against
Not recorded for this study
Kind of result
Living longer, or avoiding a major event
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated
What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.
The limits of this study, and where it came from
Main limit. No limitation is recorded for this study.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route. Intravenous
Interval reported. Not recorded in this summary
Written into the record, not signed off as a reviewed claim.
openFDA Drugs@FDA · a recorded source, not a stored snapshot
openFDA NDC Directory · a recorded source, not a stored snapshot
openFDA SPL label · a recorded source, not a stored snapshot
PubChem PUG-REST · a recorded source, not a stored snapshot
Overall survival
✗ The study did not show it
Who was studied
NCT00087711
How many people
1713
Study design
Phase 3
Compared against
Not recorded for this study
Kind of result
Living longer, or avoiding a major event
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated
What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.
The limits of this study, and where it came from
Main limit. No limitation is recorded for this study.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route. Intravenous
Interval reported. Not recorded in this summary
Written into the record, not signed off as a reviewed claim.
openFDA Drugs@FDA · a recorded source, not a stored snapshot
openFDA NDC Directory · a recorded source, not a stored snapshot
openFDA SPL label · a recorded source, not a stored snapshot
PubChem PUG-REST · a recorded source, not a stored snapshot
What we know
RNAWiki holds 6 written-up human studies for this substance, each with the question it asked.
How we know it
Each card names the study, the number of people and what the study set out to measure.
What this does not prove
These summaries were written by a person and have not been signed off as reviewed claims.
Why it matters
A study that failed is as informative as one that worked, and both are here.
What we still do not know
No reviewed claim exists, so no exact population, effect size or interval is published yet.
What is missing or unclear◇Read from sources, not yet reviewed
Were people like you studied?
RNAWiki cannot tell whether a study fits you. It can show who was in it, and where the result stops carrying.
Who was studied
People similar to this profile were included.
PEMFEXY™ is a folate analog metabolic inhibitor indicated for: in combination with pembrolizumab and platinum chemotherapy, for the initial treatment of patients with metastatic non-squamous NSCLC, with no EGFR or ALK genomic tumor aberrations. ( 1.1 ) in combination with cisplatin for the initial treatment of patients with locally advanced or metastatic non-squamous, non-small cell lung cancer (NSCLC).
Who is missing from the studies
Which groups were under-represented in the studies has not been recorded for this substance. Pregnancy, breastfeeding, children, older adults, and people with liver or kidney conditions are commonly excluded from trials; nothing here says whether they were.
What the label states about particular groups
On pediatric, the label states: “The safety and effectiveness of pemetrexed in pediatric patients have not been established.”
US prescribing information · 0f006b06-ab85-423d-ba0c-dfc3fc25844e · read 2026-08-30
On older people, the label states: “Of the 3,946 patients enrolled in clinical studies of pemetrexed, 34% were 65 and over and 4% were 75 and over.”
US prescribing information · 0f006b06-ab85-423d-ba0c-dfc3fc25844e · read 2026-08-30
On people who are pregnant, the label states: “Risk Summary Based on findings from animal studies and its mechanism of action, pemetrexed can cause fetal harm when administered to a pregnant woman [see Clinical Pharmacology ( 12.1 ) ] .”
US prescribing information · 0f006b06-ab85-423d-ba0c-dfc3fc25844e · read 2026-08-30
On people who are breastfeeding, the label states: “Risk Summary There is no information regarding the presence of pemetrexed or its metabolites in human milk, the effects on the breastfed child, or the effects on milk production.”
US prescribing information · 0f006b06-ab85-423d-ba0c-dfc3fc25844e · read 2026-08-30
Where the result stopped carrying
This is a scope explorer, not a diagnosis engine.
It shows who was studied so you can see whether people similar to you were included.
RNAWiki cannot tell whether a study fits you. It can show who was in it.
What it would be like to take◇Read from sources, not yet reviewed
Why it might seem to do nothing
A real effect and a noticed effect are different things. These are the recorded reasons the two come apart.
It was studied in different people
The people in the studies were not much like the reader.
On this record: Which groups were under-represented in the studies has not been recorded for this substance. Pregnancy, breastfeeding, children, older adults, and people with liver or kidney conditions are commonly excluded from trials; nothing here says whether they were.
A different form was studied
The studied form is not the form on the shelf.
On this record: This record is linked to 1 related forms. Evidence does not carry across all of them.
The evidence may simply be wrong
Small early studies often do not hold up.
On this record: RNAWiki has not yet published a reviewed conclusion for this use.
Other reasons RNAWiki checked and found nothing for (10)
It was studied for a different goal
The studies measured something else entirely. Nothing in this record points to this reason.
There was nothing to correct
Where a level is already normal, topping it up may change nothing. Nothing in this record points to this reason.
Something else had to happen too
In the studies it was paired with training, a diet or another treatment. Nothing in this record points to this reason.
The change is too small to feel
A real change can still sit below what a person notices. Nothing in this record points to this reason.
Day-to-day swing hides it
Sleep, food, stress and time of day move most numbers more than this would. Nothing in this record points to this reason.
Not enough time yet
The studies ran longer than the person has waited. Nothing in this record points to this reason.
It was not taken as studied
Missed days change the result, and studies count them. Nothing in this record points to this reason.
Something else changed at the same time
Two changes at once cannot be told apart afterwards. Nothing in this record points to this reason.
The product may not be what it says
Contents of a sold product are not always what the label states. Nothing in this record points to this reason.
No recorded reason
RNAWiki has nothing stored that would explain it. Nothing in this record points to this reason.
None of these is a reason to take more. Taking more is not a step this page ever suggests.
What it would be like to take◇Read from sources, not yet reviewed
What taking it involves
The recorded facts about getting hold of it and using it. Nothing here is a suggestion about what you should do.
How it is supplied
Given by a clinician
❝ Quoted from a source
Where this came from
Copied from a source RNAWiki stored, with the source named.
Read from the recorded approval status.
No source is stored against this line.
Form and route
Intravenous
✎ Source-linked record
Where this came from
A person wrote this into the record with the study named beside it. No reviewer has signed it off.
The form and route recorded on this substance.
No source is stored against this line.
Who oversees it
Professional supervision is normally required. A regulator classifies this substance in a way that restricts how it is supplied.
❝ Quoted from a source
Where this came from
Copied from a source RNAWiki stored, with the source named.
Suppression classes recorded: S1, S3, S4.
No source is stored against this line.
What is in the pack
Sold as powder, solution, injectable, injection, solution, concentrate, given by the intravenous, injection route.
✎ Source-linked record
Where this came from
A person wrote this into the record with the study named beside it. No reviewer has signed it off.
Recorded notes on how this is sold and what that means for what is in the pack.
No source is stored against this line.
Where it is registered
Regulatory records are listed in the technical disclosure at the foot of this page.
# Counted from records
Where this came from
A count of rows RNAWiki holds. It describes our records, not your body.
Register entries are stored per jurisdiction and shown with their dates.
No source is stored against this line.
Why people stop
Not recorded.
∅ Nothing recorded
Where this came from
RNAWiki holds nothing here and says so rather than guessing.
No record of why people stopped taking it is stored for this substance.
No source is stored against this line.
What it would be like to take∅Nothing found in the sources checked
What can go wrong
Sorted by where each line came from. A regulator's label and a report somebody sent in are not the same kind of fact.
∅Nothing found in the sources checked
No harm is recorded against this substance in the sources RNAWiki checked. Finding nothing is not the same as showing there is nothing.
The sources listed were searched and held nothing. That is not the same as nothing existing.
Over a long time. No completed tested study window is recorded, so long-term effects are not established by the registry record.
Groups the studies covered thinly. Which groups were under-represented in the studies has not been recorded for this substance. Pregnancy, breastfeeding, children, older adults, and people with liver or kidney conditions are commonly excluded from trials; nothing here says whether they were.
What is missing or unclear◇Read from sources, not yet reviewed
Does the exact form matter?
Evidence belongs to the exact thing that was tested. A different salt, a different mixture or a different preparation is a different question.
The form that was studied
Intravenous
✎ Source-linked record
Where this came from
A person wrote this into the record with the study named beside it. No reviewer has signed it off.
The form used in the studies cited on this page.
No source is stored against this line.
What is sold
Not recorded.
∅ Nothing recorded
Where this came from
RNAWiki holds nothing here and says so rather than guessing.
Nothing further is recorded about which forms are sold.
No source is stored against this line.
What is recorded as being sold
49 products list this as an active ingredient in the United States drug directory. 49 of them contain it and nothing else.
FDA National Drug Code directory · 83831-111 · read 2026-08-29
They are sold as injection, injection, powder, lyophilized, for solution, injection, solution, injection, solution, concentrate, powder and solution, concentrate, taken intravenous.
FDA National Drug Code directory · 83831-111 · read 2026-08-29
The regulator's established pharmacologic class for it is folate analog metabolic inhibitor [epc] and folic acid metabolism inhibitors [moa].
FDA National Drug Code directory · 83831-111 · read 2026-08-29
33 published labels name it as an active ingredient. 33 of them describe this substance alone, which is where its own label text on this page comes from.
US prescribing information · 0f006b06-ab85-423d-ba0c-dfc3fc25844e · read 2026-08-29
Those labels are classed as human prescription drug.
US prescribing information · 0f006b06-ab85-423d-ba0c-dfc3fc25844e · read 2026-08-29
PEMRYDI RTU is intravenous at 3., recorded as fda label in effect 2025-07-08 in the United States.
US prescribing information · 0f006b06-ab85-423d-ba0c-dfc3fc25844e · read 2026-08-30
Evidence carries across two names for one substance. It does not carry across a salt, a mirror form or a mixture.
This order is fixed in code and does not count clicks or time on the page.
What is not here
9 questions this page could not answer
These sections were prepared and left out because there was nothing to put in them. They are listed rather than hidden, so the gaps in this record are visible.
What was measured, goal by goal — found nothing in the sources checked.
How close this is to real life — found nothing in the sources checked.
The path through the body — found nothing in the sources checked.
Felt, measured, or meaningful — found nothing in the sources checked.
How long anything takes — found nothing in the sources checked.
What it may clash with — found nothing in the sources checked.
Other ways to the same goal — found nothing in the sources checked.
Claims that go past the evidence — found nothing in the sources checked.
What changed on this page — found nothing in the sources checked.
The record as stored
The full record, for auditing
Everything above is built from what is below. This layer keeps the technical vocabulary, record identifiers and every stored row, so a reader who wants to check the page can.
Recorded evidence blocks (9)
Q2
On the PEMETREXED, (R)- label: indicated for what?
"Pemetrexed for Injection is a folate analog metabolic inhibitor indicated: in combination with pembrolizumab and platinum chemotherapy, for the initial treatment of patients with metastatic non-squamous non-small cell lung cancer (NSCLC), with no EGFR or ALK genomic tumor aberrations. ( 1.1 ) in combination with…": indications and usage on PEMETREXED, (R)-'s label. DailyMed label · 5fb3a2d5-b9ec-4044-abb9-3e0d848a448e · 2026-08-21
Q3
928 registered trials of PEMETREXED, (R)- — at which phases?
Registered studies posting no result
619 of 928
928 registered studies of PEMETREXED, (R)-: 541 phase2, 231 phase1, 215 phase3, 16 phase4, 14 na, 11 na or unstated, 5 early phase1. CLINICALTRIALS_SNAPSHOT · 2026-09-01
terminated; "Slow accrual and evidence from other studies showing benefit of early initiation of pemetrexed after first-line therapy"
NCT00216216
terminated; "The results from the interim analysis were not favorable to continue this trial."
NCT00259285
terminated; "Trial was stopped early due to low enrollment."
NCT00265785
terminated; "Closed due to poor accrual"
NCT00268437
terminated; "Trial closed early because, during an interim analysis, the primary endpoint fell short."
14 further recorded trials
NCT00280748
terminated; "Slow accrual"
NCT00290017
terminated; "FDA Hold May 2007"
NCT00310050
terminated; "slow accrual"
NCT00321308
terminated; "See Termination Reason in Detailed Description."
NCT00351039
terminated; "slow accrual"
NCT00356525
terminated; "Stopped early due to low enrollment"
NCT00369629
terminated; "This was planned as a phase I/II study originally, but due to a lack of funding, the phase II portion was never conducted."
NCT00383266
terminated; "Low accrual"
NCT00383331
terminated; "Trial was stopped early due to low enrollment"
NCT00389688
terminated; "low accrual"
NCT00394147
terminated; "stopped for lack of efficacy"
NCT00402883
terminated; "Terminated due to bevacizumab and chemoradiotherapy toxicity"
NCT00438204
terminated; "All data collection has completed."
NCT00447421
terminated; "Interim results of another trial showed inferior activity of treatment"
recorded 2026-09-01 · last checked 2026-09-04
Q5
Human studies of PEMETREXED, (R)- used Pemetrexed 500 mg/m2 — over how long?
studies of PEMETREXED, (R)- used the recorded amount. ClinicalTrials.gov · 2026-09-01
6 recorded entries; human; also "Pemetrexed 500 mg/m2", "Pemetrexed 1000 mg/m2", "Pemetrexed 500 mg/m^2"
Show the evidence
human
NCT00191191
Pemetrexed 500 mg/m2
NCT00191191
Pemetrexed 1000 mg/m2
NCT02862457
Pemetrexed 500 mg/m^2
NCT03110484
Pemetrexed 500 MG
NCT05244837
pemetrexed 500mg/m2
NCT05299125
Pemetrexed 500 mg
recorded 2026-09-01 · last checked 2026-09-04
Q6
PEMETREXED, (R)-'s half-life is 3.5 hours — which schedules were studied?
3.5 hours, the half-life PEMETREXED, (R)-'s label states: "Elimination The total systemic clearance of pemetrexed is 91.8 mL/min and the elimination half-life of pemetrexed is 3.5 hours in patients with normal renal function (creatinine clearance of 90 mL/min)." DailyMed label · 5fb3a2d5-b9ec-4044-abb9-3e0d848a448e · 2026-08-21
Show the evidence
half lifepharmacokinetics
3.5 hours; Elimination The total systemic clearance of pemetrexed is 91.8 mL/min and the elimination half-life of pemetrexed is 3.5 hours in patients with normal renal function (creatinine clearance of 90 mL/min).
metabolismpharmacokinetics
Metabolism Pemetrexed is not metabolized to an appreciable extent.
recorded 2026-08-21 · last checked 2026-09-04
Q7
Which running trial of PEMETREXED, (R)- could settle lifespan?
NCT03351842 measures Disease-Free-Survival-Rate, reading out 2024-09-01.
95 open trials; n 460; "Surgery With or Without Chemotherapy for Stage I NSCLC With Micropapillary Component ≥ 20%"
Show the evidence
Trial
NCT03351842
"Surgery With or Without Chemotherapy for Stage I NSCLC With Micropapillary Component ≥ 20%"; n 460; "Disease-Free-Survival-Rate"; 2024-09-01
NCT06497543
"Intrathecal Pemetrexed for SCLC Patients With Refractory Brain Metastases or Leptomeninges Metastatic"; n 80; "Overall Survival"; 2026-04-30
NCT06927986
"Phase III Trial of SYS6010 Versus Platinum-based Chemotherapy for EGFR-mutated NSCLC（SYNSTAR01）"; n 380; "Progression-free survival (PFS) assessed by independent review committee (IRC)"; 2026-08-30
NCT05184712
"Phase 3 Clinical Study of AK112 for NSCLC Patients"; n 322; "Progression-free survival (PFS)"; 2026-09
NCT04892953
"Local Consolidative Therapy and Durvalumab for Oligoprogressive and Polyprogressive Stage III NSCLC After Chemoradiation and Anti-PD-L1 Therapy"; n 51; "Progression free survival (PFS)"; 2026-09-30
NCT05870319
"A Phase III Study of SKB264 for EGFR Mutant NSCLC Patients"; n 376; "Progression-free survival (PFS)"; 2026-09-30
14 further recorded trials
NCT05689671
"Pemetrexed-free vs. Pemetrexed-based Immunochemotherapy in Metastatic TTF-1 Negative Lung Adenocarcinoma"; n 136; "Overall Survival (OS)"; 2026-10
NCT03425643
"Efficacy and Safety of Pembrolizumab (MK-3475) With Platinum Doublet Chemotherapy as Neoadjuvant/Adjuvant Therapy for Participants With Resectable Stage II, IIIA, and Resectable IIIB (T3-4N2) Non-small Cell Lung Cancer (MK-3475-671/KEYNOTE-671)"; n 797; "Event Free Survival (EFS)"; 2026-10-15
NCT04129502
"TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations"; n 354; "Progression Free Survival (PFS) as Assessed by Blinded Independent Review Committee (IRC) per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1"; 2026-10-31
NCT05281406
"Additional Chemotherapy for EGFRm Patients with the Continued Presence of Plasma CtDNA EGFRm At Week 3 After Start of Osimertinib 1st-line Treatment (PACE-LUNG)"; n 50; "Progression Free Survival (PFS1)"; 2026-11
NCT05261399
"Savolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib Treatment"; n 341; "Progression-free survival (PFS) / savolitinib + osimertinib versus platinum doublet chemotherapy in participants with EGFR mutated, MET-overexpressed and/or amplified, locally advanced or metastatic NSCLC who have progressed on osimertinib."; 2026-11-23
NCT05990127
"A Study of AK104/Tislelizumab With Chemotherapy as First-line Treatment in PD-L1 TPS < 1% Non-small Cell Lung Cancer"; n 642; "Overall Survival(OS)"; 2026-11-28
NCT04166487
"Plasma-Adapted First-Line Pembro In NSCLC"; n 40; "6-month Progression Free Survival rate"; 2026-12-01
NCT04966663
"Using ctDNA to Determine Therapies for Lung Cancer"; n 66; "Relapse Free Survival"; 2026-12-01
NCT06396065
"Phase III Study of AK112 for NSCLC Patients"; n 420; "Progression-free survival (PFS)"; 2026-12-31
NCT05754853
"A Study of MRG002 Versus Investigator's Choice of Chemotherapy in the Treatment of Patients With HER2-positive Unresectable Advanced or Metastatic Urothelial Cancer"; n 290; "Overall Survival (OS)"; 2027-01
NCT04267848
"Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])"; n 1210; "Disease free survival (DFS)"; 2027-01-31
NCT05766800
"Induction Therapy With PD-1 Antibody Combined With Platinum-based Doublet Chemotherapy for Locally-advanced Non-small Cell Lung Cancer"; n 100; "Event-free survival (EFS)"; 2027-04-01
NCT05715229
"Immune Profile Selection By Fraction of ctDNA in Patients With Advanced NSCLC Treated With Immunotherapy"; n 108; "Progression Free Survival (PFS)"; 2027-04-28
NCT06440954
"Efficacy and Resistance Mechanisms of IP in NSCLC With Leptomeningeal Metastases"; n 220; "Intracranial progression-free survival (I-PFS)"; 2027-04-30
Q8
Which 151 trials of PEMETREXED, (R)- posted no result?
Posted no result
151 of 151 completed trials
Registrations
NCT00005636, NCT00003706, NCT00051493, NCT00003711, NCT00489983 and NCT00490373, and 145 more
Completion dates
oldest 2000-11; newest 2024-08-16
Show the evidence
Trial
NCT00005636
2000-11
NCT00003706
2002-06
NCT00051493
2002-12
NCT00003711
2004-09
NCT00489983
2005-03
NCT00490373
2005-04
14 further recorded trials
NCT00065533
2005-06
NCT00072865
2005-09
NCT00190801
2005-09
NCT00190840
2005-10
NCT00190762
2005-11
NCT00191347
2005-11
NCT00191503
2005-11
NCT00061464
2006-02
NCT00191412
2006-03
NCT00079872
2006-05
NCT00192088
2006-05
NCT00101842
2006-07
NCT00071136
2006-08
NCT00251550
2006-08
Q9
At the median, PEMETREXED, (R)-'s trials enrolled 72 people — anything larger?
Median enrolment
72
Largest enrolment
12000
Registered trials counted
914
Q10
PEMETREXED, (R)- and OAT3, OAT4 and TRANSPORTER: shared by which compounds?
In vitro studies indicated that pemetrexed is a substrate of OAT3 (organic anion transporter 3), a transporter that is involved in the active secretion of pemetrexed.
pharmacokinetics
Drug Interaction Studies Drugs Inhibiting OAT3 Transporter Ibuprofen, an OAT3 inhibitor, administered at 400 mg four times a day decreased the clearance of pemetrexed and increased its exposure (AUC) by approximately 20% in patients with normal renal function (creatinine clearance >80 mL/min).
pharmacokinetics
In Vitro Studies Pemetrexed is a substrate for OAT3.
pharmacokinetics
Ibuprofen, an OAT3 inhibitor inhibited the uptake of pemetrexed in OAT3-expressing cell cultures with an average [I u ]/IC 50 ratio of 0.38.
pharmacokinetics
In vitro data predict that at clinically relevant concentrations, other NSAIDs (naproxen, diclofenac, celecoxib) would not inhibit the uptake of pemetrexed by OAT3 and would not increase the AUC of pemetrexed to a clinically significant extent.
pharmacokinetics
Pemetrexed is a substrate for OAT4.
2 more recorded rows
Interaction statementpharmacokinetics
In vitro, ibuprofen and other NSAIDs (naproxen, diclofenac, celecoxib) are not inhibitors of OAT4 at clinically relevant concentrations.
Interaction statementpharmacokinetics
Drugs Metabolized by Cytochrome P450 Enzymes In vitro studies suggest that pemetrexed does not inhibit the clearance of drugs metabolized by CYP3A, CYP2D6, CYP2C9, and CYP1A2.
ClinicalTrials.gov — US Government work · mixed register set; per-register licences in docs/specs/corpus-20k-sources.md · openFDA / DailyMed — US Government work
✗ required summary fields resolved: 4 required field(s) not terminal: Why people use it, Best-supported result, Biggest unanswered question, Human evidence
✓ public claims reviewed: 0 reviewed claim(s); drafts are never rendered
✓ source coverage passed: 5 source rows
✓ no critical contamination: no quarantine open
✓ canonical metadata passed: slug and display name present
✓ no raw internal fields: enforced by the copy-contract test over the rendered page
This is a record of evidence. It is not medical advice, and it does not say this substance suits you. Nothing here says any substance on RNAWiki is appropriate for a child.